Clinical Pediatric Pneumonia Score in Critically Ill Children

Development of a Clinical Pediatric Pneumonia Score in Critically Ill Children Admitted With Acute Respiratory Failure

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02139384

Enrollment

Registered

2014-05-15

Start date

2012-08-31

Completion date

2013-01-31

Last updated

2017-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

procalcitonin, community acquired pneumonia, pneumonia score

Brief summary

The purpose of the study is to create a clinical pneumonia tool that can be used to predict the cause of community-acquired pneumonia, which is a lung infection that began outside of the hospital in critically ill children therefore limiting unnecessary antibiotic use. The investigators will enroll critically ill children admitted with acute respiratory failure and suspected pneumonia. Each patient will receive a clinical pneumonia score blinded from culture and respiratory viral panel results. All care after samples obtained will be at the discretion of the PICU team. The investigators believe that our clinical pneumonia scale with procalcitonin will accurately designate viral from bacterial etiologies.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 21 Years

Healthy volunteers

Inclusion criteria

* All intubated pediatric patients * Age 1 day to 21 years * Admitted to the LLUCH PICU with suspected pneumonia for the next 6 months * Have received antibiotics for less than 12 hours * Have been intubated for less than 24 hours * Patients must be English or Spanish speaking for consent purposes.

Exclusion criteria

* Patients who have received antibiotics for greater than 12 hours * Patients who have been intubated for greater than 24 hours * Patients who are unable to tolerate non-bronchoscopic bronchoalveolar lavage

Design outcomes

Primary

Measure	Time frame
Can our proposed pneumonia score distinguish community acquired bacterial pneumonia from community acquired viral pneumonia	6 months

Countries

United States

Outcome results